Ratings Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
32.69 ^USD	-2.24%		-6.60%	+46.79%

May. 16	Transcript : Agios Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM
May. 02	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	MT

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AGIOS PHARMACEUTICALS, INC.	+46.79%	1.9B	B-
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B	B+
BIONTECH SE	-6.20%	24.69B	B+
ARGENX SE	-2.33%	21.97B	B
GENMAB A/S	-6.03%	19.27B	A-
BEIGENE, LTD.	-13.41%	17.56B	B
WUXI APPTEC CO., LTD.	-40.50%	17.32B	A-
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B	C+
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes